1-3 of 3
Raji Sundaramoorthi
Close
Sort by
Journal Articles

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

William C. Shakespeare, PhD, Frank Wang, Ph.D., Qihong Xu, Ph.D., Xiaotian Zhu, Ph.D., Narayana Narasimham, Ph.D., Chester A. Metcalf, Ph.D., Yihan Wang, Ph.D., Raji Sundaramoorthi, Ph.D., Wei-Sheng Huang, Ph.D., Dong Zou, Ph.D., Mathew Thomas, Ph.D., Jan Romero, Ph.D., David Wen, M.S., Ingrid Chen, B.S., Lisi Cai, M.S., Shuangying Liu, M.S., Scott Wardwell, B.S., Yaoyu Ning, M.S., Jeff Keats, B.S., Joseph Snodgrass, Ph.D., Karin Russian, M.S., Marc Broudy, B.S., Thomas O’Hare, Ph.D., Caitlyn Smith, B.S., Amie Corbin, Ph.D., Brian Druker, M.D., John Iuliucci, Ph.D., David Dalgarno, Ph.D., Tomi K. Sawyer, Ph.D., Tim Clackson, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2180.
https://doi.org/10.1182/blood.V108.11.2180.2180
Published: 2006
Journal Articles

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, III, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian J. Druker, Michael W. N. Deininger
Journal: Blood
Blood (2005) 106 (1): 227–234.
https://doi.org/10.1182/blood-2004-12-4771
Published: 2005
Includes: Supplemental data
Journal Articles

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O'Hare, Roy Pollock, Eric P. Stoffregen, Jeffrey A. Keats, Omar M. Abdullah, Erika M. Moseson, Victor M. Rivera, Hao Tang, Chester A. Metcalf, III, Regine S. Bohacek, Yihan Wang, Raji Sundaramoorthi, William C. Shakespeare, David Dalgarno, Tim Clackson, Tomi K. Sawyer, Michael W. Deininger, Brian J. Druker
Journal: Blood
Blood (2004) 104 (8): 2532–2539.
https://doi.org/10.1182/blood-2004-05-1851
Published: 2004